Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Neuropathologica
Published in: Acta Neuropathologica 3/2011

01-09-2011 | Original Paper

Vasculitis-like neuropathy in amyotrophic lateral sclerosis unresponsive to treatment

Authors: Grazia Devigili, Nurcan Üçeyler, Marcus Beck, Karlheinz Reiners, Guido Stoll, Klaus V. Toyka, Claudia Sommer

Published in: Acta Neuropathologica | Issue 3/2011

Login to get access

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease with variable involvement of other systems. A pathogenetic role of immune-mediated mechanisms has been suggested. We retrospectively analyzed sural nerve pathology and the clinical course in 18 patients with ALS. These patients had undergone sural nerve biopsy because of clinical or neurophysiological signs indicating sensory involvement (ALS+). Eleven of the 18 ALS+ patients had inflammatory cell infiltrates (ALSvasc) resembling infiltrates seen in patients with vasculitic neuropathy. Data were compared with the 7 patients without vasculitic infiltrates (ALSnonvasc) and with those of 16 patients with isolated peripheral nerve vasculitis (NPvasc). Biopsy specimens were processed with standard histological stains and with immunohistochemistry for a panel of inflammatory markers, with the hypothesis that the composition of infiltrates should differ between ALSvasc and NPvasc. Immunoreactive cells were quantified in a blinded manner. Unlike patients with NPvasc, those with ALSvasc had only minor neurophysiological abnormalities in the sural nerve and, except for the infiltrates, almost normal nerve morphology on semithin sections. The difference in epineurial T cell count was significant between ALSvasc and ALSnonvasc (p = 0.031). Surprisingly, the cellular composition of epineurial infiltrates in sural nerve biopsies was indistinguishable between ALSvasc and NPvasc despite a significant difference in fiber pathology (p < 0.0001). Standard immunosuppressive treatment did not prevent clinical progression of the motor neuron disease in any of the patients with ALSvasc. ALSvasc appears as a neuropathological subtype in ALS+ suggesting immune-mediated disease components but without response to standard immunosuppressive treatment.
Appendix
Available only for authorised users
Literature
1.
Almer G, Vukosavic S, Romero N et al (1999) Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 72:2415–2425PubMedCrossRef
2.
Amoiridis G, Tsimoulis D, Ameridou I (2008) Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS. Neurology 71:779PubMedCrossRef
3.
Appel SH, Smith RG, Alexianu M et al (1995) Increased intracellular calcium triggered by immune mechanisms in amyotrophic lateral sclerosis. Clin Neurosci 3:368–374PubMed
4.
Banerjee R, Mosley RL, Reynolds AD et al (2008) Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One 3:e2740PubMedCrossRef
5.
Berghoff M, Samsam M, Muller M et al (2005) Neuroprotective effect of the immune system in a mouse model of severe dysmyelinating hereditary neuropathy: enhanced axonal degeneration following disruption of the RAG-1 gene. Mol Cell Neurosci 28:118–127PubMedCrossRef
6.
Bradley WG, Good P, Rasool CG et al (1983) Morphometric and biochemical studies of peripheral nerves in amyotrophic lateral sclerosis. Ann Neurol 14:267–277PubMedCrossRef
7.
Brooks BR, Miller RG, Swash M et al (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293–299PubMedCrossRef
8.
Collins MP, Dyck PJ, Gronseth GS et al (2010) Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst 15:176–184PubMedCrossRef
9.
Collins MP, Mendell JR, Periquet MI et al (2000) Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology 55:636–643PubMed
10.
Davies L, Spies JM, Pollard JD et al (1996) Vasculitis confined to peripheral nerves. Brain 119(Pt 5):1441–1448PubMedCrossRef
11.
Demestre M, Orth M, Wells GM et al (2005) Characterization of matrix metalloproteinases in denervated muscle. Neuropathol Appl Neurobiol 31:545–555PubMedCrossRef
12.
Desurkar A, Lin JP, Mills K et al (2009) Charcot-Marie-Tooth (CMT) disease 1A with superimposed inflammatory polyneuropathy in children. Neuropediatrics 40:85–88PubMedCrossRef
13.
Drachman DB, Chaudhry V, Cornblath D et al (1994) Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol 35:142–150PubMedCrossRef
14.
Dyck PJ, Benstead TJ, Conn DL et al (1987) Nonsystemic vasculitic neuropathy. Brain 110(Pt 4):843–853PubMedCrossRef
15.
Echaniz-Laguna A, Degos B, Mohr M et al (2006) A study of three patients with amyotrophic lateral sclerosis and a polyneuropathy resembling CIDP. Muscle Nerve 33:356–362PubMedCrossRef
16.
Edgar JM, McCulloch MC, Montague P et al (2010) Demyelination and axonal preservation in a transgenic mouse model of Pelizaeus-Merzbacher disease. EMBO Mol Med 2:42–50PubMedCrossRef
17.
Elliott JL (2001) Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res Mol Brain Res 95:172–178PubMedCrossRef
18.
Fang L, Huber-Abel F, Teuchert M et al (2009) Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS). J Neurol Sci 285:62–66PubMedCrossRef
19.
20.
Ghezzi P, Bernardini R, Giuffrida R et al (1998) Tumor necrosis factor is increased in the spinal cord of an animal model of motor neuron degeneration. Eur Cytokine Netw 9:139–144PubMed
21.
Ginsberg L, Malik O, Kenton AR et al (2004) Coexistent hereditary and inflammatory neuropathy. Brain 127:193–202PubMedCrossRef
22.
Hamada M, Hanajima R, Terao Y et al (2007) Median nerve somatosensory evoked potentials and their high-frequency oscillations in amyotrophic lateral sclerosis. Clin Neurophysiol 118:877–886PubMedCrossRef
23.
Hammad M, Silva A, Glass J et al (2007) Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS. Neurology 69:2236–2242PubMedCrossRef
24.
Hilz MJ, Axelrod FB, Hermann K et al (1998) Normative values of vibratory perception in 530 children, juveniles and adults aged 3–79 years. J Neurol Sci 159:219–225PubMedCrossRef
25.
26.
Ip CW, Kroner A, Kohl B et al (2009) Tacrolimus (FK506) causes disease aggravation in models for inherited peripheral myelinopathies. Neurobiol Dis 33:207–212PubMedCrossRef
27.
Isaacs JD, Dean AF, Shaw CE et al (2007) Amyotrophic lateral sclerosis with sensory neuropathy: part of a multisystem disorder? J Neurol Neurosurg Psychiatry 78:750–753PubMedCrossRef
28.
Kawamura Y, Dyck PJ, Shimono M et al (1981) Morphometric comparison of the vulnerability of peripheral motor and sensory neurons in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 40:667–675PubMedCrossRef
29.
Kerkhoff H, Jennekens FG, Troost D et al (1991) Nerve growth factor receptor immunostaining in the spinal cord and peripheral nerves in amyotrophic lateral sclerosis. Acta Neuropathol 81:649–656PubMedCrossRef
30.
Kerkhoff H, Troost D, Louwerse ES et al (1993) Inflammatory cells in the peripheral nervous system in motor neuron disease. Acta Neuropathol 85:560–565PubMedCrossRef
31.
Kimura J (2001) Electrodiagnosis in diseases of nerve and muscle: principles and practice, 3rd edn. Oxford University Press, New York
32.
Kobsar I, Berghoff M, Samsam M et al (2003) Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the recombination activating gene-1. Brain 126:804–813PubMedCrossRef
33.
Li M, Ona VO, Guegan C et al (2000) Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288:335–339PubMedCrossRef
34.
Lincecum JM, Vieira FG, Wang MZ et al (2010) From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet 42:392–399PubMedCrossRef
35.
Lorenzl S, Narr S, Angele B et al (2006) The matrix metalloproteinases inhibitor Ro 28–2653 (correction of Ro 26–2853) extends survival in transgenic ALS mice. Exp Neurol 200:166–171PubMedCrossRef
36.
Mantovani S, Garbelli S, Pasini A et al (2009) Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J Neuroimmunol 210:73–79PubMedCrossRef
37.
Martini R, Toyka KV (2004) Immune-mediated components of hereditary demyelinating neuropathies: lessons from animal models and patients. Lancet Neurol 3:457–465PubMedCrossRef
38.
Mondelli M, Rossi A, Passero S et al (1993) Involvement of peripheral sensory fibers in amyotrophic lateral sclerosis: electrophysiological study of 64 cases. Muscle Nerve 16:166–172PubMedCrossRef
39.
Pugdahl K, Fuglsang-Frederiksen A, de Carvalho M et al (2007) Generalised sensory system abnormalities in amyotrophic lateral sclerosis: a European multicentre study. J Neurol Neurosurg Psychiatry 78:746–749PubMedCrossRef
40.
Rajabally YA, Jacob S (2008) Chronic inflammatory demyelinating polyneuropathy-like disorder associated with amyotrophic lateral sclerosis. Muscle Nerve 38:855–860PubMedCrossRef
41.
Sakai K, Komai K, Yanase D et al (2005) Plasma VEGF as a marker for the diagnosis and treatment of vasculitic neuropathy. J Neurol Neurosurg Psychiatry 76:296PubMedCrossRef
42.
Schmidt B, Toyka KV, Kiefer R et al (1996) Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 19:474–487PubMedCrossRef
43.
Shefner JM, Tyler HR, Krarup C (1991) Abnormalities in the sensory action potential in patients with amyotrophic lateral sclerosis. Muscle Nerve 14:1242–1246PubMedCrossRef
44.
Theys PA, Peeters E, Robberecht W (1999) Evolution of motor and sensory deficits in amyotrophic lateral sclerosis estimated by neurophysiological techniques. J Neurol 246:438–442PubMedCrossRef
Metadata
Title
Vasculitis-like neuropathy in amyotrophic lateral sclerosis unresponsive to treatment
Authors
Grazia Devigili
Nurcan Üçeyler
Marcus Beck
Karlheinz Reiners
Guido Stoll
Klaus V. Toyka
Claudia Sommer
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Acta Neuropathologica / Issue 3/2011
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-011-0837-8

Other articles of this Issue 3/2011

Acta Neuropathologica 3/2011 Go to the issue

Original Paper

Peroxisomal alterations in Alzheimer’s disease

Original Paper

The cerebellar component of Friedreich’s ataxia

Correspondence

Spinocerebellar ataxia type 2 (SCA2) is associated with TDP-43 pathology

Original Paper

Vascular β-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAβ mice

Original Paper

Cholinergic imbalance in the multiple sclerosis hippocampus

Correspondence

High frequency of IDH-1 mutation links glioneuronal tumors with neuropil-like islands to diffuse astrocytomas